Mereo BioPharma Q3 net loss narrows 17% to $5.86 million

Bitget2026/11/09 13:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Mereo BioPharma’s third-quarter 2026 net loss narrowed 17% year over year to $5.86 million.
Revenue reached $800,000, while research and development expenses fell 51% year over year to $2.09 million.
Cash and cash equivalents totaled $26.1 million at September 30, expected to fund operations into late 2027.
Regulatory discussions with partner Ultragenyx continue to assess a potential path forward for setrusumab in pediatric osteogenesis imperfecta.
Work with Sentynl continues to refine alvelestat’s Phase 3 trial design, with preparations targeting a potential early-2027 study launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mereo BioPharma Group plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090800PRIMZONEFULLFEED9872887) on November 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Mereo BioPharma Q3 net loss narrows 17% to $5.86 million

You may also like

Crypto prices